Current Clinical Trials in Dry AMD and the Definition of Appropriate Clinical Outcome Measures

REFERENCES

• Klein R, Klein BE, Linton KL. Prevalence of age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology 1992;99:933–943.
   PubMed Web of Science ®Google Scholar
• Friedman DS, O’Colmain BJ, Muñoz B et al.; Eye Diseases Prevalence Research Group. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 2004;122:564–572.
   PubMed Web of Science ®Google Scholar
• Ferris FL, Davis MD, Clemons TE et al.; Age-Related Eye Disease Study (AREDS) Research Group. A simplified severity scale for age-related macular degeneration: AREDS Report No. 18. Arch Ophthalmol 2005;123:1570–1574.
   PubMed Web of Science ®Google Scholar
• Sarks JP, Sarks SH, Killingsworth MC. Evolution of geographic atrophy of the retinal pigment epithelium. Eye (Lond) 1988;2 (Pt 5):552–577.
   PubMedGoogle Scholar
• Sunness JS. The natural history of geographic atrophy, the advanced atrophic form of age-related macular degeneration. Mol Vis 1999;5:25.
   PubMed Web of Science ®Google Scholar
• Holz FG, Bindewald-Wittich A, Fleckenstein M et al.; FAM-Study Group. Progression of geographic atrophy and impact of fundus autofluorescence patterns in age-related macular degeneration. Am J Ophthalmol 2007;143:463–472.
   PubMed Web of Science ®Google Scholar
• Klein R, Meuer SM, Knudtson MD, Klein BE. The epidemiology of progression of pure geographic atrophy: the Beaver Dam Eye Study. Am J Ophthalmol 2008;146:692–699.
   PubMed Web of Science ®Google Scholar
• Sunness JS, Gonzalez-Baron J, Applegate CA et al. Enlargement of atrophy and visual acuity loss in the geographic atrophy form of age-related macular degeneration. Ophthalmology 1999;106:1768–1779.
   PubMed Web of Science ®Google Scholar
• Lindblad AS, Lloyd PC, Clemons TE et al.; Age-Related Eye Disease Study Research Group. Change in area of geographic atrophy in the Age-Related Eye Disease Study: AREDS report number 26. Arch Ophthalmol 2009;127:1168–1174.
   PubMedGoogle Scholar
• Yehoshua Z, Rosenfeld PJ, Gregori G et al. Progression of geographic atrophy in age-related macular degeneration imaged with spectral domain optical coherence tomography. Ophthalmology 2011;118:679–686.
   PubMed Web of Science ®Google Scholar
• Sunness JS, Margalit E, Srikumaran D et al. The long-term natural history of geographic atrophy from age-related macular degeneration: enlargement of atrophy and implications for interventional clinical trials. Ophthalmology 2007;114:271–277.
   PubMed Web of Science ®Google Scholar
• Fleckenstein M, Adrion C, Schmitz-Valckenberg S et al.; FAM-Study Group. Concordance of disease progression in bilateral geographic atrophy due to AMD. Invest Ophthalmol Vis Sci 2010;51:637–642.
   PubMedGoogle Scholar
• Fleckenstein M, Schmitz-Valckenberg S, Martens C et al. Fundus Autofluorescence and Spectral Domain Optical Coherence Tomography Characteristics in a Rapidly Progressing Form of Geographic Atrophy IOVS iovs.10-7021; published ahead of print February 10, 2011, doi:10.1167/iovs.10-7021.
   Google Scholar
• Yates JR, Sepp T, Matharu BK et al.; Genetic Factors in AMD Study Group. Complement C3 variant and the risk of age-related macular degeneration. N Engl J Med 2007;357:553–561.
   PubMed Web of Science ®Google Scholar
• Edwards AO, Ritter R 3rd, Abel KJ et al. Complement factor H polymorphism and age-related macular degeneration. Science 2005;308:421–424.
   PubMed Web of Science ®Google Scholar
• Francis PJ, Zhang H, Dewan A, Hoh J, Klein ML. Joint effects of polymorphisms in the HTRA1, LOC387715/ARMS2, and CFH genes on AMD in a Caucasian population. Mol Vis 2008;14:1395–1400.
   PubMed Web of Science ®Google Scholar
• Scholl HP, Fleckenstein M, Fritsche LG et al. CFH, C3 and ARMS2 are significant risk loci for susceptibility but not for disease progression of geographic atrophy due to AMD. PLoS ONE 2009;4:e7418.
   PubMed Web of Science ®Google Scholar
• Klein ML, Ferris FL 3rd, Francis PJ et al. Progression of geographic atrophy and genotype in age-related macular degeneration. Ophthalmology 2010;117:1554–1559, 1559.e1.
   Google Scholar
• A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol. 2001;119:1417–1436; PMID:11594942.
   PubMed Web of Science ®Google Scholar
• Evans J. Antioxidant supplements to prevent or slow down the progression of AMD: a systematic review and meta-analysis. Eye (Lond) 2008;22:751–760.
   PubMed Web of Science ®Google Scholar
• Thornton J, Edwards R, Mitchell P et al. Smoking and age-related macular degeneration: a review of association. Eye (Lond) 2005;19:935–944.
   PubMed Web of Science ®Google Scholar
• Seddon JM, Cote J, Rosner B. Progression of age-related macular degeneration: association with dietary fat, transunsaturated fat, nuts, and fish intake. Arch Ophthalmol 2003;121:1728–1737.
   PubMed Web of Science ®Google Scholar
• Ding X, Patel M, Chan CC. Molecular pathology of age-related macular degeneration. Prog Retin Eye Res 2009;28:1–18.
   PubMed Web of Science ®Google Scholar
• Dunaief JL, Dentchev T, Ying GS, Milam AH. The role of apoptosis in age-related macular degeneration. Arch Ophthalmol 2002;120:1435–1442.
   PubMedGoogle Scholar
• Hageman GS, Luthert PJ, Victor Chong NH et al. An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE–Bruch’s membrane interface in aging and age-related macular degeneration. Prog Retin Eye Res 2001;20:705–732.
   PubMed Web of Science ®Google Scholar
• Lutty G, Grunwald J, Majji AB, Uyama M, Yoneya S. Changes in choriocapillaris and retinal pigment epithelium in age-related macular degeneration. Mol Vis 1999;5:35.
   PubMed Web of Science ®Google Scholar
• McLeod DS, Taomoto M, Otsuji T et al. Quantifying changes in RPE and choroidal vasculature in eyes with age-related macular degeneration. Invest Ophthalmol Vis Sci 2002;43:1986–1993.
   PubMed Web of Science ®Google Scholar
• Curcio CA, Medeiros NE, Millican CL. Photoreceptor loss in age-related macular degeneration. Invest Ophthalmol Vis Sci 1996;37:1236–1249.
   PubMed Web of Science ®Google Scholar
• Johnson PT, Brown MN, Pulliam BC, Anderson DH, Johnson LV. Synaptic pathology, altered gene expression, and degeneration in photoreceptors impacted by drusen. Invest Ophthalmol Vis Sci 2005;46:4788–4795.
   PubMed Web of Science ®Google Scholar
• Zhang K, Hopkins JJ, Heier JS et al. Ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for treatment of geographic atrophy in age-related macular degeneration. Proc Natl Acad Sci USA 2011;108:6241–6245.
   PubMed Web of Science ®Google Scholar
• Sunness JS, Rubin GS, Broman A et al. Low luminance visual dysfunction as a predictor of subsequent visual acuity loss from geographic atrophy in age-related macular degeneration. Ophthalmology 2008;115:1480–1488, 1488.e1.
   PubMedGoogle Scholar
• Parodi MB, Virgili G, Evans JR. Laser treatment of drusen to prevent progression to advanced age-related macular degeneration. Cochrane Database Syst Rev. 2009: CD006537.
   PubMedGoogle Scholar
• Csaky KG, Richman EA, Ferris FL 3rd. Report from the NEI/FDA Ophthalmic Clinical Trial Design and Endpoints Symposium. Invest Ophthalmol Vis Sci 2008;49:479–489.
   PubMed Web of Science ®Google Scholar
• Bartlett H, Eperjesi F. Use of fundus imaging in quantification of age-related macular change. Surv Ophthalmol 2007;52:655–671.
   PubMed Web of Science ®Google Scholar
• Davis MD, Gangnon RE, Lee LY et al.; Age-Related Eye Disease Study Group. The Age-Related Eye Disease Study severity scale for age-related macular degeneration: AREDS Report No. 17. Arch Ophthalmol 2005;123:1484–1498.
   PubMed Web of Science ®Google Scholar
• Sunness JS, Ziegler MD, Applegate CA. Issues in quantifying atrophic macular disease using retinal autofluorescence. Retina (Philadelphia, Pa) 2006;26:666–672.
   PubMedGoogle Scholar
• Scholl HP, Peto T, Dandekar S et al. Inter- and intra-observer variability in grading lesions of age-related maculopathy and macular degeneration. Graefes Arch Clin Exp Ophthalmol 2003;241:39–47.
   PubMed Web of Science ®Google Scholar
• Pirbhai A, Sheidow T, Hooper P. Prospective evaluation of digital non-stereo color fundus photography as a screening tool in age-related macular degeneration. Am J Ophthalmol 2005;139:455–461.
   PubMed Web of Science ®Google Scholar
• Sunness JS, Bressler NM, Tian Y, Alexander J, Applegate CA. Measuring geographic atrophy in advanced age-related macular degeneration. Invest Ophthalmol Vis Sci 1999;40:1761–1769.
   PubMedGoogle Scholar
• Smith RT, Chan JK, Nagasaki T et al. Automated detection of macular drusen using geometric background leveling and threshold selection. Arch Ophthalmol 2005;123:200–206.
   PubMed Web of Science ®Google Scholar
• Schmitz-Valckenberg S, Holz FG, Bird AC, Spaide RF. Fundus autofluorescence imaging: review and perspectives. Retina (Philadelphia, Pa) 2008;28:385–409.
   PubMed Web of Science ®Google Scholar
• Drexler W, Sattmann H, Hermann B et al. Enhanced visualization of macular pathology with the use of ultrahigh-resolution optical coherence tomography. Arch Ophthalmol 2003;121:695–706.
   PubMedGoogle Scholar
• Gregori G, Wang F, Rosenfeld PJ et al. Spectral domain optical coherence tomography imaging of drusen in nonexudative age-related macular degeneration. Ophthalmology 2011 PMID:21388687.
   Google Scholar
• Khanifar AA, Koreishi AF, Izatt JA, Toth CA. Drusen ultrastructure imaging with spectral domain optical coherence tomography in age-related macular degeneration. Ophthalmology 2008;115:1883–1890.
   PubMed Web of Science ®Google Scholar
• Jiao S, Knighton R, Huang X, Gregori G, Puliafito C. Simultaneous acquisition of sectional and fundus ophthalmic images with spectral-domain optical coherence tomography. Opt Express 2005;13:444–452.
   PubMedGoogle Scholar
• Lujan BJ, Wang F, Gregori G et al. Calibration of fundus images using spectral domain optical coherence tomography. Ophthalmic Surg Lasers Imaging 2008;39:S15–S20.
   Google Scholar
• Wojtkowski M, Srinivasan V, Fujimoto JG et al. Three-dimensional retinal imaging with high-speed ultrahigh-resolution optical coherence tomography. Ophthalmology 2005;112:1734–1746.
   PubMed Web of Science ®Google Scholar
• Ralston PG Jr, Sloan D, Waters-Honcu D et al. A pilot, open-label study of the safety of MC-1101 in both normal volunteers and patients with early nonexudative age-related macular degeneration. Invest Ophthalmol Vis Sci. 2010;51:E-Abstract 913.
   Google Scholar
• Tao W, Wen R, Goddard MB et al. Encapsulated cell-based delivery of CNTF reduces photoreceptor degeneration in animal models of retinitis pigmentosa. Invest Ophthalmol Vis Sci 2002;43:3292–3298.
   PubMed Web of Science ®Google Scholar
• Beltran WA, Zhang Q, Kijas JW et al. Cloning, mapping, and retinal expression of the canine ciliary neurotrophic factor receptor alpha (CNTFRalpha). Invest Ophthalmol Vis Sci 2003;44:3642–3649.
   PubMed Web of Science ®Google Scholar
• Emerich DF, Thanos CG. NT-501: an ophthalmic implant of polymer-encapsulated ciliary neurotrophic factor-producing cells. Curr Opin Mol Ther 2008;10:506–515.
   PubMed Web of Science ®Google Scholar
• Mata NL, Vogel R. Pharmacologic treatment of atrophic age-related macular degeneration. Curr Opin Ophthalmol 2010;21:190–196.
   PubMedGoogle Scholar
• Saylor M, McLoon LK, Harrison AR, Lee MS. Experimental and clinical evidence for brimonidine as an optic nerve and retinal neuroprotective agent: an evidence-based review. Arch Ophthalmol 2009;127:402–406.
   PubMed Web of Science ®Google Scholar
• Johnson LV, Leitner WP, Rivest AJ et al. The Alzheimer’s A beta-peptide is deposited at sites of complement activation in pathologic deposits associated with aging and age-related macular degeneration. Proc Natl Acad Sci USA 2002;99:11830–11835.
   PubMed Web of Science ®Google Scholar
• Ding JD, Lin J, Mace BE et al. Targeting age-related macular degeneration with Alzheimer’s disease based immunotherapies: anti-amyloid-beta antibody attenuates pathologies in an age-related macular degeneration mouse model. Vision Res 2008;48:339–345.
   PubMed Web of Science ®Google Scholar
• Beatty S, Boulton M, Henson D, Koh HH, Murray IJ. Macular pigment and age related macular degeneration. Br J Ophthalmol 1999;83:867–877.
   PubMed Web of Science ®Google Scholar
• Kennedy CJ, Rakoczy PE, Constable IJ. Lipofuscin of the retinal pigment epithelium: a review. Eye (Lond) 1995;9 (Pt 6):763–771.
   PubMed Web of Science ®Google Scholar
• Radu RA, Han Y, Bui TV et al. Reductions in serum vitamin A arrest accumulation of toxic retinal fluorophores: a potential therapy for treatment of lipofuscin-based retinal diseases. Invest Ophthalmol Vis Sci 2005;46:4393–4401.
   PubMed Web of Science ®Google Scholar
• Kubota R, Birch D, David R. Phase 1, dose-escalating study of the safety, tolerability, and pharmacokinetics of ACU-4429 in healthy volunteers. Invest Ophthalmol Vis Sci. 2009;50: E-Abstract 5009.
   Google Scholar
• Beatty S, Koh H, Phil M, Henson D, Boulton M. The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv Ophthalmol 2000;45:115–134.
   PubMed Web of Science ®Google Scholar
• Risk factors associated with age-related macular degeneration. A case-control study in the age-related eye disease study: Age-Related Eye Disease Study Report Number 3. Ophthalmology. 2000;107:2224–2232.
   PubMed Web of Science ®Google Scholar
• Tanito M, Li F, Elliott MH, Dittmar M, Anderson RE. Protective effect of TEMPOL derivatives against light-induced retinal damage in rats. Invest Ophthalmol Vis Sci 2007;48:1900–1905.
   PubMed Web of Science ®Google Scholar
• Sternberg P, Rosenfeld PJ, Slakter JS et al. Topical OT-551 for treating geographic atrophy: phase II results. Invest Ophthalmol Vis Sci. 2010;51: E-Abstract 6416.
   Google Scholar
• Wong WT, Kam W, Cunningham D et al. Topical administration of anti-oxidant, OT-551 for the treatment of geographic atrophy: results of a phase I/II clinical trial. Invest Ophthalmol Vis Sci. 2010;51:E-Abstract 6418.
   Google Scholar
• Gehrs KM, Jackson JR, Brown EN, Allikmets R, Hageman GS. Complement, age-related macular degeneration and a vision of the future. Arch Ophthalmol 2010;128:349–358.
   PubMedGoogle Scholar
• Anderson DH, Radeke MJ, Gallo NB et al. The pivotal role of the complement system in aging and age-related macular degeneration: hypothesis re-visited. Prog Retin Eye Res 2010;29:95–112.
   PubMed Web of Science ®Google Scholar
• Skeie JM, Fingert JH, Russell SR, Stone EM, Mullins RF. Complement component C5a activates ICAM-1 expression on human choroidal endothelial cells. Invest Ophthalmol Vis Sci 2010;51:5336–5342.
   PubMed Web of Science ®Google Scholar
• Patel M, Chan CC. Immunopathological aspects of age-related macular degeneration. Semin Immunopathol 2008;30:97–110.
   PubMed Web of Science ®Google Scholar
• Nozaki M, Raisler BJ, Sakurai E et al. Drusen complement components C3a and C5a promote choroidal neovascularization. Proc Natl Acad Sci USA 2006;103:2328–2333.
   PubMed Web of Science ®Google Scholar
• Holers ea. TT30, a Novel Human Protein Therapeutic, Selectively Modulates the Complement Alternative Pathway by Targeted Supplementation of Local Factor H Activity. 51st Annual Meeting of the American Society of Hematology, New Orleans, LA, 2009.
   Google Scholar
• Risitano ea. TT30, A Novel Regulator of the Complement Alternative Pathway (CAP), Inhibits Hemolysis of Paroxysmal Nocturnal Hemoglobinuria (PNH) Erythrocytes and Prevents Upstream C3 Binding On Their Surface in An In Vitro Model. 51st Annual Meeting of the American Society of Hematology, New Orleans, LA, 2009.
   Google Scholar
• Landa G, Butovsky O, Shoshani J, Schwartz M, Pollack A. Weekly vaccination with copaxone (glatiramer acetate) as a potential therapy for dry age-related macular degeneration. Curr Eye Res 2008;33:1011–1013.
   PubMed Web of Science ®Google Scholar